Method of treating drug-induced liver injury in children suffering from tuberculosis. RU patent 2473346.

FIELD: medicine.

SUBSTANCE: declared invention refers to medicine. The anti-tuberculosis preparations are cancelled, while Ursosal 20 mg/kg is single administered per os, and Enterosgel 10-15 g for 3 days. Then, a dose of Ursosan is reduced to 12-15 mg/kg a day with underlying reinitiation of the anti-tuberculosis preparations, and the Ursosan therapy is continued until the ALT value appears to be below an upper limit of normal.

EFFECT: method under invention enables higher clinical effectiveness in the drug-induced liver injury in children.

1 tbl, 3 dwg, 2 ex

IPC classes for russian patent Method of treating drug-induced liver injury in children suffering from tuberculosis. RU patent 2473346. (RU 2473346):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K31/695 -

A61K31/575 -

Another patents in same IPC classes:

Method of treating non-alcoholic fatty liver disease / 2473342
Invention relates to medicine, namely to gastroenterology and can be used for treatment of non-alcoholic fatty liver disease. For this purpose administered are metronidasol 250 mg 4 times per day, alpha-normix 200 mg 2 tablets x 2 times per day during 7-10 days.After that, treatment is performed with further administration of bifiform in dose 2 capsules in the morning, probifor in dose 25-30 doses 3 times per day, linex in dose 2 capsules 3 times per day, hylak forte 40-60 drops 3 times per day, sporobacterin 2-4 ml. Duration of intake constitutes 3-4 weeks, also administered is dufalak in dose 5-10 ml per day. Drug therapy of lipid metabolism disorders is performed in dependence of biochemical parameters: in case if ultrasonic signs of steatosis are present and level of transaminases is normal, statins in combination with ezetimibe are administered. If transaminases increase to 3 normal values, essential phospholipids are applied during 3 months. If transaminases increase higher than 3 normal values, ursodeoxycholic acid in dose 15-20 mg/kg is applied; if ultrasonic signs of non-alcoholic steato hepatitis are present and transaminases increase to 3 normal values, statins are administered in dose 20 mg and ursodeoxycholic acid in dose 15-20 mg/kg for 3-6 months. If transaminases increase higher than 3 normal values, treatment is performed with statins in dose 20-40 mg/day and ursodeoxycholic acid in dose 15-20 mg/kg, ezetimibe in dose 10 mg 1 time per day.

Method of preventing vertical transmission of hepatitis b and c viruses in pregnant women with reactivation of viruses in third trimester / 2473341
Invention relates to field of medicine, namely to infectious diseases and obstetrics, and can be used for prevention of vertical transmission of hepatitis B and C viruses in pregnant women. For this purpose in pregnant women with term of pregnancy from 28 to 30 weeks with reactivation of chronic viral hepatitis B and C, level of viral load is determined and if its value is higher than 105 copies/ml, preparation Kipferon is introduced in dose 2 suppositories 2 times per day rectally with 12 hour interval during 14 days, and starting from 36 weeks of pregnancy repeated course is carried out in accordance with the same scheme.

Method of treating non-alcoholic steatohepatitis with application of dalargin magnetophoresis / 2473325
Invention relates to medicine, gastroenterology. Method includes dietotherapy in accordance with diet No 5, exercise therapy. Additionally intake of low-mineralised carbonaceous chloride-hydrocarbonate-sulfate-sodium-calcium mineral water "Essentuki-Novaya" is realised. Water is taken in in dose 3.5 ml per 1 kg of patient's body weight, 3 times per day, 30-40 minutes before meal. Carbonaceous-hydrogen sulfide mineral baths with content of hydrogen sulfide 15-20 mg/l are carried out every second day. Baths are taken with water temperature 36-37°C. Course includes 8-10 procedures. Dalargin magnetophoresis on liver projection is performed daily. Pulsing travelling magnetic field from apparatus AMO-ATOS is used. Magnetophoresis is carried out with induction 45 mT, with modulation frequency 10 Hz for 15 minutes, course includes 10 procedures.

Agent normalising liver mitochondria / 2470655
Invention refers to medicine, more specifically pharmacology. Grape seed extract is presented as an agent normalising liver mitochondria.

Agent possessing antiarrhythmic and hepatoprotective properties / 2469720
Invention refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide of formula I: as an agent possessing antiarrhythmic and hepatoprotective properties. The invention also refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide for preparing pharmaceutical compositions.

Use of polydatine for treating hepatic diseases and polydatine pharmaceutical composition / 2468803
There are presented the use of polydatine for treating toxic (including drug-induced) and alcoholic hepatic diseases, as well as based oral compositions. What is shown is reduction of a degree of hepatocyte adipose degeneration in sub-acute alcoholisation, reduction of glycemia and lactate-acidosis. Polydactine promoted reduction of synthesis and accumulation of glycosaminoglycans.

Method of preventing chronic toxic hepatopathy / 2468446
In order to prevent chronic toxic hepatopathy melaxen is introduced to animals in experiment one time per day in dose 10 mg/ml through probe into stomach. Simultaneously intragastric introduction of cobalt chloride solution in dose 2 mg/kg, in terms of metal, is performed daily, to create cobalt intoxication in organism.

Method for preparing agent showing cholagogue action / 2465000
Invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.

Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

Agent of saussurea ds plants possessing hepatoprotective action / 2464036
Invention refers to pharmaceutical industry, particularly to an agent possessing hepatoprotective activity and an ability to normalise the hepatic function. The use of a ground elevated part of Saussurea plants or an aqueous or aqueous-alcoholic or supercritical fluid extract of the elevated part of Saussurea plants as the agent possessing hepatoprotective activity and the ability to normalise the hepatic function.

Silicon-titanium-containing polyol derivatives and hydrogels based thereon / 2458929
Invention relates to novel biologically active chemical compounds - silicon-titanium-containing polyol derivatives (glycerine, polyethylene glycol), as well as hydrogels based thereon. Disclosed are silicon-titanium-containing polyol derivatives, having transcutaneous, wound healing and regenerating activity, the composition of which in excess of polyol has the formula k(CH3)4-nSi(O-R-OH)n·Ti(O-R-OH)4·xHO-R-OH, where R=R1=CH2-CH(OH)-CH2: k=1 or 2, n=2 or 3, x=11 or 12; or R=R2=(CH2-CH2-O-)7,7CH2-CH2: k=1 or 2, n=2-4, x=2 or 3, with dynamic viscosity 1.5-90.0 Pa·s (25±0.5°C), obtained by reacting (methyl)ethoxysilane and tetrabutoxytitanium with polyol in molar ratio (1-2):1:(18-22) for R1 or (1-2):1:(8-15) for R2, respectively, while heating the reaction mass to temperature 90-140°C and holding at that temperature for not less than 6 hours with intense stirring, followed by removal of the formed alcohols. The invention also discloses hydrogels based on said polyol derivatives, containing water and a gelling additive, with the following ratio of components (wt %): silicon-titanium-containing polyol derivatives in excess of polyol - 70.730-94.970; gelling additive 0.002-0.060; water - the balance.

Method of enteral detoxification accompanying treating immune disorders / 2455012
Invention refers to medicine and aims at enteral detoxification accompanying treating immune disorders. It involves prescribing a relaxant prebiotic and an enterosorbent. The relaxant prebiotic is introduced in a therapeutic dose 8-12 hours prior to the introduction of the enterosorbent. Once a day in the therapeutic course of 3-5 days. If the relaxant action of the prebiotic appeared to be ineffective, it is prescribed again in the half therapeutic dose. Lactulose is used as said prebiotic. The enterosorbent is activated carbon, Polysorb MP, Enterosgel, Lactofiltrum.

Vertebrata digestive tract detoxicant / 2452491
Invention relates to veterinary science. A detoxicant of polysilicic acid derivatives is specified in a group of reversed-phase sorbents.

Method of treating purulent-necrotic hoof injures in cattle / 2449798
Invention refers to veterinary medicine. A method consists in the fact that injured areas are repeatedly coated every 3-5 days with an ointment with high penetrating and healing effect on the basis of organosilicone glycerohydrogel of the following composition Si(C3H8O3)4·xC3H8O3·yH2O wherein 5≤x≤6; 28≤y≤30; as active substances, it contains antimicrobial preparations pefloxacin, metronidazole and chlorhexidine bigluconate in the following proportions, wt %: pefloxacin 1.0÷1.5, metronidazole 1.0÷1.5, chlorhexidine bigluconate 0.005÷0.01, organosilicone glycerohydrogel - up to 100. Treating severe hoof injures and hoof detachment also requires introducing the drug into a hoof cavity by means of a syringe to fill up the cavity.

Quinolone derivatives or its pharmaceutically acceptable salt / 2440987
Present invention is related to new quinolone derivatives of general formula (I) where R1: C3-6cycloalkyl or lower alkylene C3-6cycloalkyl, R2: -H or halogen, R3: -H, halogen, -OR0 or -O-(lower alkylene)-phenyl, R0: are the same or different from each other, and each represents -H or lower alkyl, R4: lower alkyl, halogen(lower alkyl), lower alkyleneC3-6cycloalkyl, C3-7cycloalkyl or a heterocyclic group, where cycloalkyl and the heterocyclic group specified in R4 can be respectively substituted, R5: -NO2, -CN, -L-Ra, -C(O)R0, -O-Rb, -N(R6)2, lower alkylene-N(R6)(Rc), -N(R6)C(O)-Rd, lower alkylene-N(R6)C(O)-Rd, lower alkylene-N(R0)C(O)O-(lower alkyl), -N(R0)C(O)N(R0)-Re, lower alkylene-N(R0)C(O)N(R0)-Re, -N(R0)S(O)2N(R0)C(O)-Rd, -CH=NOH, C3-6cycloalkyl, (2,4-dioxo-1,3-thiazolidin-5-yliden)methyl or (4-oxo-2-tioxo-1,3-thiazolidin-5-yliden)methyl where cycloalkyl specified in R5 can be respectively substituted, R6: H, lower alkyl, lower alkylene-CO2R0 or lower alkylene-P(O)((OPp)2, where lower alkylene specified in R6 can be substituted, L: lower alkylene or lower alkenylene which can be respectively substituted, Ra: -OR0, -O-(lower alkylene)-phenyl, -O-(lower alkylene)-CO2R0, -CO2R0, -C(O)NHOH, -C(O)N(R6)2, -C(O)N(R0)-S(O)2-(lower alkyl), -C(O)N(R0)-S(O)2-phenyl, -C(O)N(R0)-S(O)2-(heterocyclic group), -NH2OH, -OC(O)R0, -OC(O)-(halogen(lower alkyl)), -P(O)(ORp)2, phenyl or the heterocyclic group where phenyl or the heterocyclic group specified in Ra can be substituted, Rp: R0, lower alkylene-OC(O)-(lower alkyl), lower alkylene-OC(O)-C3-6cycloalkyl, lower alkylene-OC(O)O-(lower alkyl), Rb: H, lower alkylene-Rba or lower alkenylene-Rba where lower alkylene or lower alkenylene specified in Rb can be substituted, Rba: -OR0, -CO2R0, -C(O)N(R0)2, -C(O)N(R0)-S(O)2-(lower alkyl), -C(O)N(R0)-S(O)2-[phenyl, -C(NH2)-NOH, -C(NH2)=NO-C(O)-(lower alkylene)-C(O)R0, -CO2-(lower alkylene)-phenyl, -P(O)(ORp)2, -C(O)R0, -C(O)-phenyl, C3-6cycloalkyl, phenyl or the heterocyclic group where phenyl and the heterocyclic group specified in Rba can be substituted, Rc: H, lower alkylene-OR0, lower alkylene-CO2R0, lower alkylene-P(O)((OPp)2, phenyl where lower alkylene and phenyl are specified in Rd can be substituted, Rd: C1-7-alkyl, lower alkenyl, halogen(lower alkyl), lower alkylene-Rda, lower alkylenylene-Rda, C3-6cycloalkyl, phenyl, naphthyl or the heterocyclic group, where lower alkylene, cycloalkyl, phenyl, naphthyl and the heterocyclic group specified in Rd can be substituted, Rda: -CN, -OR0, -O-(lower alkylene)-CO2R0, -O-naphthyl, -CO2R0, -CO2-(lower alkylene)-N(R0)2, -P(O)(ORp)2, -N(R6)2, -C(O)N(R0)-phenyl, -C(O)N(R0)-(lower alkylene which can be used by -CO2R0)-phenyl, -N(R0)C(O)-phenyl, -N(R0)C(O)-OR0, -N(R0)C(O)-O-(lower alkylene)-phenyl, -N(R0)S(O)2-phenyl, C3-6cycloalkyl, phenyl, naphthyl or the heterocyclic group, where phenyl, naphthyl and heterocyclic group specified in Ra can be substituted, Re: lower alkylene-CO2R0, phenyl, -S(O)2-phenyl or -S(O)2-(heterocyclic group), where phenyl and the heterocyclic group specified in Re can be substituted, X: CH, A: C(R7), R7: -H, or R4 and R7 together can form lower alkylene, where the substituted groups have the substituted specified in cl.1, and provided 7-(cyclohexylamino)-1-ethyl-6-fluor-4-oxo-1,4-dohydroquinoline-3-carbonitryl is excluded. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I) and application of formula (I) for preparing a thrombocyte aggregation inhibitor or a P2Y12 inhibitor.

Method of transmembrane dialysis of purulent wounds / 2433839
Invention relates to medicine, namely, to surgery, and can be applied for treatment of purulent wounds of various etiology. For this purpose on surface of purulent wound applied is membrane capsule, filled with sorbent. As membrane capsule used is membrane bandage, which consists of polypropylene capsule, which hermetically fixed on it film. Cavity of polypropylene capsule is connected with membrane film, made from polyhydroxyalkanoate with pore size 2.7-3.0 nm, and is filled with dialysing solution, which consists of mixture of 100 ml Octenisept and 6 grams of enterosorbent Polysorb MP. Replacement of dialysing solution in membrane bandage is carried out in postoperative period daily during 10-12 days.

Method of polychemotherapeutic enteropathy prevention and treatment / 2405546
Invention belongs to medicine, notably to oncology, and can be used in prevention and treatment of enteropathy due to intensive cytostatic polychemotherapy. To achieve this Enterosgel (Methylsiliconic acid hydrogel) is administered during whole course of polychemotherapy and after it. After cytostatic treatment during Enterosgel administration additionally nonabsorbable enteral antiseptic ersefuril is administered. normobiotics - Hylac-forte and Primadophilus™ Bifidus are administered when level of leukocytes in blood gets higher then 1000/mcl.

Agent and method for treatment of endometritis in cows / 2404756
Invention relates to the field of veterinary science, in particular to methods and agents for treatment of obstetric-gynaecological diseases in cows. Agent contains pefloxacin, metronidazole and chlorhexidine bigluconate, and the base is represented - water-soluble organosilicic derivative of glycerin, having transmucosal activity, composition of which complies with the formula (CH3)2Si(C3H7O3)2·C3H8O3, at the following ratio of components in the agent, wt %: pefloxacin 0.75-1.0; metronidazole 1.0-1.5; chlorhexidine bigluconate 0.05-0.1; water-soluble organosilicic compound - glycerin derivative - up to 100. According to proposed method, introduction of specified agent is carried out in process of complex therapy intrauterinely 3-5 times, with interval of 48 hours, in amount of 50-100 g per single introduction with the help of Janet's syringe and polystyrene pipette for artificial insemination, at the same time prior to introduction the agent is dissolved with sterile distilled water in the ratio of 1:1.

Method of conservative treatment of acute pancreatitis / 2402353
Invention refers to medicine, namely to surgery and endocrinology, and can be used in the patients requiring a conservative treatment of acute pancreatitis. That is ensured by a standard medical therapy by the introduction of infusion preparations, anaesthetics, spasmolytics, vasoconstrictors, antibiotics, novocaine, cytostatics, omeprazole, sandostatin. For the period of treatment, hunger with voluminous drinking is prescribed. Pit of the stomach is cooled. In addition, procaine blocks in the round ligament of liver are applied that implements the introduction of at least 200 mg of Immunomax and 10 ml of 5-fluorouracil. During 2 days, at least 1.0 g of metronidazole, 0.1 g of furaginum, at least 15.0 g of Enterosgel are intaken. During the whole therapeutic course, at least 1 ml of Sporobacterine suspension together with cooled water is taken once a day. Starting from the sixth day and during the whole therapeutic course of hospital treatment, 1 tablet of Mezym forte 2 times a day is prescribed. For at least two weeks after discharge from the hospital, treatment in a locally available health resort is continued.

Method of treating liver cancer / 2401660
Inventions relate to medicine, namely to oncology, and deals with treatment of liver cancer. For this purpose 4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid or its physiologically acceptable salt in dose from 10 to 30 mg per day is introduced. Treatment is carried out in accordance with therapeutic regimen, in accordance to which continuous daily introduction for from 1 to 4 weeks is performed. After that period of medication withdrawal for from 1 to 3 weeks follows.